

TECENTRIQ[®] is NOW FDA APPROVED for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ.¹

To learn more, please visit TECENTRIQ.com

Codes for Your Reference ¹			
Type	Code	Description	
NDC ¹	50242-917-01 50242-0917-01	Carton containing one 1200 mg/20 mL single-dose vial	
ICD-10-CM ²			
C34.00	Malignant neoplasm of unspecified main bronchus	C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.01	Malignant neoplasm of right main bronchus	C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.02	Malignant neoplasm of left main bronchus	C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung		
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung		

Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantees concerning reimbursement or coverage for any service or item.

Abbreviations: ICD-10-CM, International Classification of Diseases, 10th revision, Clinical Modification; NDC, National Drug Code.

IMPORTANT SAFETY INFORMATION

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include immune-related serious adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, and other immune-related adverse events. Other warnings and precautions include infection, infusion-related reactions, and embryo-fetal toxicity.

Please see additional Important Safety Information on following page and in accompanying full Prescribing Information.

DISTRIBUTION AND FULFILLMENT INFORMATION

- TECENTRIQ is available through authorized specialty distributors and wholesalers via the TECENTRIQ distribution network
- For additional network information, please contact Genentech BioOncology® Access Solutions by calling 1-888-249-4918 or by visiting www.genentech-access.com/tecentriq/hcp

PATIENT ACCESS INFORMATION

- Genentech BioOncology Access Solutions offers a full range of access and reimbursement support for your patients and practice to minimize delays in therapy and understand patient coverage and out-of-pocket costs
- For information on distribution and patient access support, please contact Genentech BioOncology Access Solutions for TECENTRIQ by calling 1-888-249-4918 or by visiting www.genentech-access.com/tecentriq/hcp

For additional information, please contact your Genentech representative.

IMPORTANT SAFETY INFORMATION

Serious Adverse Reactions

Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

- **Immune-related pneumonitis.** Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 pneumonitis
- **Immune-related hepatitis.** Immune-mediated hepatitis, including a fatal case in urothelial carcinoma (UC), and liver test abnormalities occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 immune-mediated hepatitis
- **Immune-related colitis.** Immune-mediated colitis or diarrhea, including a fatal case of diarrhea-associated renal failure in UC, occurred. Permanently discontinue TECENTRIQ for Grade 4 diarrhea or colitis
- **Immune-related endocrinopathies.** Immune-related thyroid disorders, adrenal insufficiency, hypophysitis, and type 1 diabetes mellitus, including diabetic ketoacidosis, have occurred. Permanently discontinue TECENTRIQ for Grade 4 hypophysitis
- **Other immune-related adverse reactions.** Meningoencephalitis, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, ocular inflammatory toxicity, and pancreatitis, including increases in serum amylase and lipase levels, have occurred. Permanently discontinue TECENTRIQ for any grade of meningitis or encephalitis, or any grade of myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome. Permanently discontinue TECENTRIQ for Grade 4 or any grade of recurrent pancreatitis
- **Infection.** Severe infections, including fatal cases, occurred. Sepsis, herpes encephalitis, and mycobacterial infection leading to retroperitoneal hemorrhage have been observed
- **Infusion-related reactions.** Severe infusion reactions have occurred. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion reactions
- **Embryo-fetal toxicity.** TECENTRIQ can cause fetal harm in pregnant women. Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
- Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

Most Common Adverse Reactions

The most common adverse reactions (rate $\geq 20\%$) included fatigue (46%), decreased appetite (35%), dyspnea (32%), cough (30%), nausea (22%), musculoskeletal pain (22%), and constipation (20%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.

References: 1. TECENTRIQ [package insert]. South San Francisco, CA: Genentech, Inc; 2016. 2. ICD-10-CM Tabular List of Diseases and Injuries. 2016 Code Tables and Index. Centers for Medicare & Medicaid Services (CMS) website. <https://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-CM-and-GEMs.html>. Updated October 8, 2015. Accessed August 17, 2016.



Genentech
A Member of the Roche Group